Overview

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Status:
Recruiting

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Carboplatin
Osimertinib
Paclitaxel
Pemetrexed